Following a limited submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Eslicarbazepine acetate (Zebinix®) is recommended as an option for restricted use within NHS Wales. Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations, within its licensed indication as adjunctive therapy in adults, adolescents and children aged above six years, with partial onset seizures, with or without secondary generalisation. Eslicarbazepine acetate (Zebinix®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | eslicarbazepine acetate (Zebinix®) | ||
| Formulation | 200 mg tablet, 800 mg tablet, 50 mg/ml oral suspension | ||
| Reference number | 1214 | ||
| Indication | Adjunctive therapy in adolescents and children aged above six years, with partial-onset seizures with or without secondary generalisation. Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations |
||
| Company | Eisai Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Limited | ||
| Status | Recommended with restrictions | ||
| Advice number | 1019 | ||
| NMG meeting date | 08/05/2019 | ||
| AWMSG meeting date | 19/06/2019 | ||
| Date of issue | 25/06/2019 | ||
| Date of last review | June 2022 | ||
| Further information This advice incorporates and replaces the AWMSG recommendation for eslicarbazepine acetate (Zebinix ® ) as an option for restricted use within NHS Wales. Eslicarbazepine acetate should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations, within its licensed indication as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalisation (advice number 3512, originally published November 2012). |
|||